Hepatic miR-33a/miR-144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects

Liver International

Volumn 36, Issue 9, 2016, Pages 1383-1391

  Vega Badillo, Joel ^a,b   Gutiérrez Vidal, Roxana ^a,b   Hernández Pérez, Hugo A ^b   Villamil Ramírez, Hugo ^b   León Mimila, Paola ^a,b   Sánchez Muñoz, Fausto ^c   Morán Ramos, Sofía ^b   Larrieta Carrasco, Elena ^d   Fernández Silva, Itzel ^e   Méndez Sánchez, Nahúm ^f   Tovar, Armando R ^d   Campos Pérez, Francisco ^e   Villarreal Molina, Teresa ^g   Hernández Pando, Rogelio ^d   Aguilar Salinas, Carlos A ^d   Canizales Quinteros, Samuel ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e Hospital General Dr Ruben Leñero   (Mexico)

^f LIVER RESEARCH UNIT   (Mexico)

^g INMEGEN   (Mexico)

Author keywords

ABCA1; ABCG1; miR 144; miR 33a b NASH

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE BETA SUBUNIT; ABC TRANSPORTER A1; ABC TRANSPORTER G1; CARNITINE O OCTANOYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MICRORNA; MICRORNA 144; MICRORNA 33A; MICRORNA 33B; OXIDOREDUCTASE; TOLL LIKE RECEPTOR 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ABCA1 PROTEIN, HUMAN; ABCG1 PROTEIN, HUMAN; CHOLESTEROL; MIRN144 MICRORNA, HUMAN; MIRN33 MICRORNA, HUMAN;

ADULT; ARTICLE; BARIATRIC SURGERY; CONTROLLED STUDY; FATTY ACID OXIDATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LIPID LIVER LEVEL; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEXICAN; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; COMPLICATION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER; METABOLISM; MEXICO; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; ATP BINDING CASSETTE TRANSPORTER 1; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 1; BARIATRIC SURGERY; CHOLESTEROL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; MALE; MEXICO; MICRORNAS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; TRIGLYCERIDES; YOUNG ADULT;

EID: 84961742993     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13109     Document Type: Article

References (36)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387–95.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31.
3. Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis 2004; 8:861–79, ix.
4. Puri P, Baillie RA, Wiest MM, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081–90.
5. Caballero F, Fernández A, De Lacy AM, et al. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 2009; 50: 789–96.
6. Van Rooyen DM, Larter CZ, Haigh WG, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141:1393–403, 1403.e1–5.
7. Gelissen IC, Harris M, Rye K-A, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006; 26: 534–40.
8. Timmins JM, Lee J-Y, Boudyguina E, et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005; 115: 1333–42.
9. Min H-K, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15: 665–74.
10. Rayner KJ, Suárez Y, Dávalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328: 1570–3.
11. Dávalos A, Goedeke L, Smibert P, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA 2011; 108: 9232–7.
12. Ramírez CM, Rotllan N, Vlassov AV, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res 2013; 112: 1592–601.
13. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121: 2921–31.
14. Li D, Wang X, Lan X, et al. Down-regulation of miR-144 elicits proinflammatory cytokine production by targeting toll-like receptor 2 in nonalcoholic steatohepatitis of high-fat-diet-induced metabolic syndrome E3 rats. Mol Cell Endocrinol 2015; 402: 1–12.
15. Gastrointestinal surgery for severe obesity. National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992; 55: 615S–9S.
16. León-Mimila P, Villamil-Ramírez H, Villalobos-Comparán M, et al. Contribution of common genetic variants to obesity and obesity-related traits in Mexican children and adults. PLoS ONE 2013; 8: e70640.
17. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1): S62–9.
19. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21.
20. Folch J, Lees M. SLOANE STANLEY GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497–509.
21. Patel DC, Albrecht C, Pavitt D, et al. Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS ONE 2011; 6: e22142.
22. Ozasa H, Ayaori M, Iizuka M, et al. Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies. Atherosclerosis 2011; 219: 141–50.
23. Tomita K, Teratani T, Suzuki T, et al. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 2014; 59: 154–69.
24. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013; 52: 175–91.
25. Liu W, Qin L, Yu H, Lv F, Wang Y. Apolipoprotein A–I and adenosine triphosphate-binding cassette transporter A1 expression alleviates lipid accumulation in hepatocytes. J Gastroenterol Hepatol 2014; 29: 614–22.
26. Yang Y, Jiang Y, Wang Y, An W. Suppression of ABCA1 by unsaturated fatty acids leads to lipid accumulation in HepG2 cells. Biochimie 2010; 92: 958–63.
27. Ahn SB, Jang K, Jun DW, Lee BH, Shin KJ. Expression of liver X receptor correlates with intrahepatic inflammation and fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2014; 59: 2975–82.
28. Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol 2013; 37: 17–29.
29. Marí M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4: 185–98.
30. Basso F, Freeman L, Knapper CL, et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res 2003; 44: 296–302.
31. Tsubakio-Yamamoto K, Matsuura F, Koseki M, et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun 2008; 375: 390–4.
32. Marquart TJ, Allen RM, Ory DS, Baldán A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 2010; 107: 12228–32.
33. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478: 404–7.
34. Rottiers V, Obad S, Petri A, et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med 2013; 5:212ra162.
35. Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA 2005; 11: 1753–61.
36. Brown BD, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007; 25: 1457–67.